Abstract: To investigate the clinical significance of serum albumin (ALB) level in the prognosis of classical Hodgkin's Lymphoma ( CHL ) patients. Methods: Clinical data from 96 pathologically confirmed, previously untreated CHL patients in Sun Yat-Sen University Cancer Center between May 2001 and December 2008 were analyzed. Overall survival ( OS ) and failure free survival (FFS) were compared in terms of ALB levels. Results: Before treatment, 17 patients had ALB < 35 g/L and 79 patients had ALB ≥ 35 g/L among the 96 CHL patients. Comparison of the baseline clinical characteristics of the two groups revealed no significant differences in age, gender, Ann Arbor staging, bulky mass, extranodal involvement, lymph nodal sites, and lactate dehydrogenase ( LDH ) level ( P > 0.05 ). The 5-year FFS rates for patients with ALB < 35 g/L and ALB ≥ 35 g/L were 60.1% and 91.6%, respectively ( P = 0.028 ), but OS had no statistical significance ( P = 0.131 ). Multivariate analysis showed that the only independent adverse prognostic factor of FFS was ALB < 35 g/L ( P = 0.030 ), and age ≥ 60 was an independent prognostic predictor of OS ( P = 0.020 ). Conclusion: The ALB level at diagnosis is of clinical significance in the prognosis of CHL. For both early and advanced CHL patients, ALB might be a novel prognostic indicator.